Glycomimetics Inc. buy stratec
Start price
12.04.19
/
50%
€11.19
Target price
04.11.21
€8.00
Performance (%)
-84.81%
End price
05.11.21
€1.70
Summary
This prediction ended on 05.11.21 with a price of €1.70. The BUY prediction by stratec for Glycomimetics Inc. performed very badly with a performance of -84.81%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Glycomimetics Inc. | 0.000% | 0.000% | -85.815% | -88.071% |
| iShares Core DAX® | -0.552% | 3.281% | 15.052% | 17.017% |
| iShares Nasdaq 100 | -1.415% | 4.535% | 26.243% | 54.337% |
| iShares Nikkei 225® | -0.877% | -1.739% | 4.897% | 4.751% |
| iShares S&P 500 | -0.415% | 3.239% | 23.253% | 46.758% |
Comments by stratec for this prediction
In the thread Glycomimetics Inc. diskutieren
GlycoMimetics is undervalued at current price
The shares are undervalued considering the company has two Phase 3 assets in rivipansel and uproleselan with data for the former expected by the end of Q2. Rivipansel aims to reduce duration of sickle cell disease related pain crises and hospitalization times. The analyst Piper Jaffray views 'the drug as a $1.5B opportunity that is not fully priced into the stock and sees "significant upside from two relatively de-risked programs."
Kursziel geändert auf 8,0
In the thread Trading Glycomimetics Inc.
Die von stratec gewählte maximale Laufzeit wurde überschritten